Try our Advanced Search for more refined results
October 02, 2014
JAZZ PHARMACEUTICALS, INC. et al v. PAR PHARMACEUTICAL, INC.
Case Number:
2:14-cv-06150
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
January 14, 2015
CORRECTED: PTAB Nixes Biz Method Review Of Jazz Drug Patents
The Patent Trial and Appeal Board on Tuesday rejected petitions challenging Jazz Pharmaceuticals Inc.'s patents for the narcolepsy drug Xyrem under the America Invents Act business method review program, ruling that the patents are not financial in nature, as required by the program. (Correction: An earlier story incorrectly stated that this decision was the first time the PTAB has ruled that a patent being challenged under the business review program was not related to financial services. The error has been corrected.)
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login